IMV vaccine adjuvant technology of choice For Dana-Farber’s HPV-related cancer clinical trial April 8, 2014 Immunovaccine Inc., a clinical stage vaccine company, today announced that its DepoVax™ adjuvanting technology will underlie the design of a new cancer vaccine trial that will be conducted by the Dana-Farber Cancer Institute to treat cervical and head and neck cancer. In a competitive process, …
Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens
March 3, 2014 Genocea Biosciences, Inc., a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company’s proprietary ATLAS™ platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches. “ATLAS™ has proven …